Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis

Immune-related adverse events (irAEs) have been reported to be associated with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate that irAEs could predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients. Literature on the correlation betwee...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-03, Vol.11, p.631949-631949
Main Authors: Wang, Donghui, Chen, Cen, Gu, Yanli, Lu, Wanjun, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Song, Yong, Zhang, Fang
Format: Article
Language:English
Subjects:
efficacy
immune checkpoint inhibitors (ICIS)
immune-related adverse events (irAEs)
lung cancer
meta-analysis
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune-related adverse events (irAEs) have been reported to be associated with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate that irAEs could predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients. Literature on the correlation between irAEs and the efficacy of immunotherapy in lung cancer patients were searched to collect the data on objective response rate (ORR), overall survival (OS), or progression-free survival (PFS) of the patients. These data were incorporated into the meta-analysis. A total of 34 records encompassing 8,115 patients were examined in this study. The irAEs occurrence was significantly associated with higher ORR {risk ratio (RR): 2.43, 95% confidence interval (CI) [2.06-2.88], < 0.00001} and improved OS {hazard ratio (HR): 0.51, 95% CI [0.43-0.61], < 0.00001}, and PFS (HR: 0.50, 95% CI [0.44-0.57],  < 0.00001) in lung cancer patients undergoing ICIs. Subgroup analysis revealed that OS was significantly longer in patients who developed dermatological (OS: HR: 0.53, 95%CI [0.42-0.65], < 0.00001), endocrine (OS: HR: 0.55, 95%CI [0.45-0.67], < 0.00001), and gastrointestinal irAEs (OS: HR: 0.58, 95%CI [0.42-0.80], = 0.0009) than in those who did not. However, hepatobiliary, pulmonary, and high-grade (≥3) irAEs were not correlated with increased OS and PFS. The occurrence of irAEs in lung cancer patients, particularly dermatological, endocrine, and gastrointestinal irAEs, is a predictor of enhanced ICIs efficacy.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.631949